Cargando…
Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation
The ionotropic glutamate receptors (NMDAR) are composed of large complexes of multi-protein subunits creating ion channels in the cell plasma membranes that allow for influx or efflux of mono- or divalent cations (e.g., Ca(2+)) important for synaptic transmissions, cellular migration and survival. R...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134353/ https://www.ncbi.nlm.nih.gov/pubmed/24739903 http://dx.doi.org/10.1038/jid.2014.190 |
_version_ | 1782330869363507200 |
---|---|
author | Prickett, Todd D. Zerlanko, Brad J. Hill, Victoria K. Gartner, Jared J. Qutob, Nouar Jiang, Jiji Simaan, May Wunderlich, John Gutkind, J. Silvio Rosenberg, Steven A. Samuels, Yardena |
author_facet | Prickett, Todd D. Zerlanko, Brad J. Hill, Victoria K. Gartner, Jared J. Qutob, Nouar Jiang, Jiji Simaan, May Wunderlich, John Gutkind, J. Silvio Rosenberg, Steven A. Samuels, Yardena |
author_sort | Prickett, Todd D. |
collection | PubMed |
description | The ionotropic glutamate receptors (NMDAR) are composed of large complexes of multi-protein subunits creating ion channels in the cell plasma membranes that allow for influx or efflux of mono- or divalent cations (e.g., Ca(2+)) important for synaptic transmissions, cellular migration and survival. Recently, we discovered the high prevalence of somatic mutations within one of the ionotropic glutamate receptors, GRIN2A, in malignant melanoma. Functional characterization of a subset of GRIN2A mutants demonstrated a loss of NMDAR complex formation between GRIN1 and GRIN2A, increased anchorage-independent growth in soft agar, and increased migration. Somatic mutation of GRIN2A results in a dominant negative effect inhibiting the tumor suppressive phenotype of wild type GRIN2A in melanoma. Depletion of endogenous GRIN2A in melanoma cells expressing wild-type GRIN2A resulted in increased proliferation compared to control. In contrast, shRNA depletion of GRIN2A in mutant cell lines slightly reduced proliferation. Our data shows that somatic mutation of GRIN2A results in increased survival and is the first such report to demonstrate the functional importance of GRIN2A mutations in melanoma and the significance ionotropic glutamate receptor signaling plays in malignant melanoma. |
format | Online Article Text |
id | pubmed-4134353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
record_format | MEDLINE/PubMed |
spelling | pubmed-41343532015-03-01 Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation Prickett, Todd D. Zerlanko, Brad J. Hill, Victoria K. Gartner, Jared J. Qutob, Nouar Jiang, Jiji Simaan, May Wunderlich, John Gutkind, J. Silvio Rosenberg, Steven A. Samuels, Yardena J Invest Dermatol Article The ionotropic glutamate receptors (NMDAR) are composed of large complexes of multi-protein subunits creating ion channels in the cell plasma membranes that allow for influx or efflux of mono- or divalent cations (e.g., Ca(2+)) important for synaptic transmissions, cellular migration and survival. Recently, we discovered the high prevalence of somatic mutations within one of the ionotropic glutamate receptors, GRIN2A, in malignant melanoma. Functional characterization of a subset of GRIN2A mutants demonstrated a loss of NMDAR complex formation between GRIN1 and GRIN2A, increased anchorage-independent growth in soft agar, and increased migration. Somatic mutation of GRIN2A results in a dominant negative effect inhibiting the tumor suppressive phenotype of wild type GRIN2A in melanoma. Depletion of endogenous GRIN2A in melanoma cells expressing wild-type GRIN2A resulted in increased proliferation compared to control. In contrast, shRNA depletion of GRIN2A in mutant cell lines slightly reduced proliferation. Our data shows that somatic mutation of GRIN2A results in increased survival and is the first such report to demonstrate the functional importance of GRIN2A mutations in melanoma and the significance ionotropic glutamate receptor signaling plays in malignant melanoma. 2014-04-16 2014-09 /pmc/articles/PMC4134353/ /pubmed/24739903 http://dx.doi.org/10.1038/jid.2014.190 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Prickett, Todd D. Zerlanko, Brad J. Hill, Victoria K. Gartner, Jared J. Qutob, Nouar Jiang, Jiji Simaan, May Wunderlich, John Gutkind, J. Silvio Rosenberg, Steven A. Samuels, Yardena Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
title | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
title_full | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
title_fullStr | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
title_full_unstemmed | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
title_short | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
title_sort | somatic mutation of grin2a in malignant melanoma results in loss of tumor suppressor activity via aberrant nmdar complex formation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134353/ https://www.ncbi.nlm.nih.gov/pubmed/24739903 http://dx.doi.org/10.1038/jid.2014.190 |
work_keys_str_mv | AT pricketttoddd somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT zerlankobradj somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT hillvictoriak somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT gartnerjaredj somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT qutobnouar somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT jiangjiji somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT simaanmay somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT wunderlichjohn somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT gutkindjsilvio somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT rosenbergstevena somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation AT samuelsyardena somaticmutationofgrin2ainmalignantmelanomaresultsinlossoftumorsuppressoractivityviaaberrantnmdarcomplexformation |